Modelled DT Structure
Method: multi-sequence alignment based machine learning
Detail: Structure Info
General Information of DT | |||||
---|---|---|---|---|---|
DT ID | DTD0009 | ||||
Gene Name | SLC22A3 | ||||
Protein Name | Organic cation transporter 3 | ||||
Gene ID | |||||
UniProt ID | |||||
TCDB ID | |||||
3D Structure |
Modelled DT Structure Method: multi-sequence alignment based machine learning Detail: Structure Info |
||||
Synonyms | OCT3; EMT; EMTH; Extraneuronal monoamine transporter; SLC22A3; Solute carrier family 22 member 3 | ||||
DT Family | Major Facilitator Superfamily (MFS) | ||||
Organic Cation Transporter (OCT) Family | |||||
Tissue Specificity | Highly expressed in the kidney, liver, placenta, heart, and skeletal muscle,to a lesser extent, in other organs including the lung and brain, as well as in cancer-derived cell lines | ||||
Function | This transporter may play a significant role in the disposition of cationic neurotoxins and neurotransmitters in the brain and mediate potential-dependent transport of a variety of organic cations. | ||||
Disease(s) | Cataract [ICD-11: 9B10] | ||||
Neurogenic shock [ICD-11: MG40.Y] | |||||
Respiratory allergies [ICD-11: 4A80] | |||||
Type 2 diabetes [ICD-11: 5A11] | |||||
Severe mood disorders [ICD-11: 6A8Z] | |||||
Endogenous Substrate(s) | Monoamines | ||||
Variability Data of This Drug Transporter (DT) | |||||
Regulatory Variability Data of This DT (VARIDT 3.0) |
|||||
(α) Microbiota Influence of This DT |
|||||
(β) Post-translational Modification of This DT |
|||||
(γ) Transcriptional Regulation of This DT |
|||||
(δ) Epigenetic Regulation of This DT |
|||||
(ε) Exogenous Modulation of This DT |
|||||
Structural Variability Data of This DT (VARIDT 2.0) |
|||||
(β) Inter-species Structural Differences |
|||||
General Variability Data of This DT (VARIDT 1.0) |
|||||
(α) Genetic Polymorphisms of This DT |
|||||
(β) Disease-specific Protein Abundances of This DT |
|||||
(γ) Species- and Tissue-specific DT Abundances |
|||||
Molecular Transporting Profile of This DT | |||||
Full List of Drug(s) Transported by This DT |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 10 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
Acetylcholine
|
Approved | Drug Info | Cataract | 9B10 | [1] |
Amphetamine
|
Approved | Drug Info | Attention deficit hyperactivity disorder | 6A05 | [2] |
Clonidine
|
Approved | Drug Info | High blood pressure | BA00 | [3] |
Entecavir
|
Approved | Drug Info | Chronic hepatitis B infection | 1E51.0 | [4] |
Epinephrine
|
Approved | Drug Info | Asthma | CA23 | [5] |
Ergotidine
|
Approved | Drug Info | Migraine | 8A80 | [5] |
Metformin
|
Approved | Drug Info | Type 2 diabetes | 5A11 | [6] |
Norepinephrine
|
Approved | Drug Info | Septic shock | 1G41 | [5] |
Propranolol
|
Approved | Drug Info | Migraine | 8A80 | [3] |
Sodium chloride
|
Approved | Drug Info | Severe mood disorders | 6A8Z | [7] |
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 2 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Indication | ICD 11 | Ref |
Etilefrine
|
Withdrawn | Drug Info | Hypotension | BA2Z | [8] |
N-methylpyridinium
|
Preclinical | Drug Info | Colon cancer | 2B90.Z | [9] |
Endogenous Metabolites (EMs) Handled by This DT |
|||||
Endogenous Metabolites (EMs) |
Click to Show/Hide the Full List of EMs: 3 EMs in Total | ||||
EM Name | PubChem CID | Detail | Experimental Material | Ref | |
Epinephrine | EM Info | Identified using HEK293 cells-OCT3 | [5] | ||
Histamine | EM Info | Identified using HEK293 cells-OCT3 | [5] | ||
Norepinephrine | EM Info | Identified using HEK293 cells-OCT3 | [5] | ||
Drug-DT Affinity Assessed by Cell Line |
|||||
Approved Drug |
Click to Show/Hide the Full List of Drug: 6 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
Epinephrine | Approved | Drug Info | Human embryonic kidney cells (HEK293)-OCT3 | Km = 240 microM | [5] |
Ergotidine | Approved | Drug Info | Human embryonic kidney cells (HEK293)-OCT3 | Km = 180 microM | [10] |
Ergotidine | Approved | Drug Info | Human embryonic kidney cells (HEK293)-OCT3 | Km = 220 microM | [5] |
Metformin | Approved | Drug Info | Chinese hamster ovary (CHO) cells-OCT3 | Km = 2260 microM | [6] |
Norepinephrine | Approved | Drug Info | Human embryonic kidney cells (HEK293)-OCT3 | Km = 510 microM | [11] |
Norepinephrine | Approved | Drug Info | Human embryonic kidney cells (HEK293)-OCT3 | Km = 2630 microM | [5] |
Withdrawn, Discontinued or Preclinical Drug |
Click to Show/Hide the Full List of Drug: 2 Drugs in Total | ||||
Drug Name | Highest Status | Detail | Cell Line | Affinity | Ref |
Etilefrine | Withdrawn | Drug Info | Chinese hamster ovary (CHO) cells-OCT3 | Km = 2800 microM | [8] |
N-methylpyridinium | Preclinical | Drug Info | Human retinal pigment epithelial (HRPE) cells-OCT3 | Km = 47 microM | [9] |
References | |||||
1 | Organic cation transporters: physiology, toxicology and special focus on ethidium as a novel substrate. Curr Drug Metab. 2009 Jul;10(6):617-31. | ||||
2 | Interaction of organic cation transporter 3 (SLC22A3) and amphetamine. J Neurochem. 2010 Jul;114(1):142-9. | ||||
3 | Influx Transport of Cationic Drug at the Blood-Retinal Barrier: Impact on the Retinal Delivery of Neuroprotectants. Biol Pharm Bull. 2017;40(8):1139-1145. | ||||
4 | Multiple SLC and ABC Transporters Contribute to the Placental Transfer of Entecavir. Drug Metab Dispos. 2017 Mar;45(3):269-278. | ||||
5 | Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain. Neuropharmacology. 2006 Jun;50(8):941-52. | ||||
6 | Expression of organic cation transporters OCT1 (SLC22A1) and OCT3 (SLC22A3) is affected by genetic factors and cholestasis in human liver. Hepatology. 2009 Oct;50(4):1227-40. | ||||
7 | Organic cation transporter 3 (Slc22a3) is implicated in salt-intake regulation. J Neurosci. 2004 Mar 17;24(11):2846-51. | ||||
8 | Drug specificity and intestinal membrane localization of human organic cation transporters (OCT). Biochem Pharmacol. 2005 Dec 5;70(12):1851-60. | ||||
9 | Structure, function, and regional distribution of the organic cation transporter OCT3 in the kidney. Am J Physiol Renal Physiol. 2000 Sep;279(3):F449-58. | ||||
10 | Selective substrates for non-neuronal monoamine transporters. Mol Pharmacol. 1999 Jul;56(1):1-10. | ||||
11 | Molecular identification of the corticosterone-sensitive extraneuronal catecholamine transporter. Nat Neurosci. 1998 Sep;1(5):349-51. | ||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.